MCID: GLC008
MIFTS: 39

Glucose Metabolism Disease

Categories: Genetic diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Glucose Metabolism Disease

MalaCards integrated aliases for Glucose Metabolism Disease:

Name: Glucose Metabolism Disease 11 14 16
Glucose Metabolism Disorders 43 71
Disorder of Glucose Metabolism 11

Classifications:



External Ids:

Disease Ontology 11 DOID:4194
MeSH 43 D044882
NCIt 49 C53655
SNOMED-CT 68 126877002
UMLS 71 C1257958

Summaries for Glucose Metabolism Disease

MalaCards based summary: Glucose Metabolism Disease, also known as glucose metabolism disorders, is related to diabetes mellitus and prediabetes syndrome. An important gene associated with Glucose Metabolism Disease is PINK1-AS (PINK1 Antisense RNA), and among its related pathways/superpathways are Cell differentiation - expanded index and miRNAs involvement in the immune response in sepsis. The drugs Insulin glargine and Lopinavir have been mentioned in the context of this disorder. Affiliated tissues include liver, spinal cord and endothelial.

Related Diseases for Glucose Metabolism Disease

Diseases related to Glucose Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 461)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus 32.6 SERPINA3 MIR29A MIR223 MIR210 MIR21 MIR17
2 prediabetes syndrome 32.6 MIR29A MIR21 MIR126 INS GCG
3 type 2 diabetes mellitus 31.5 SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
4 carbohydrate metabolic disorder 31.1 SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
5 body mass index quantitative trait locus 11 31.1 SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
6 non-alcoholic fatty liver disease 30.9 MIR21 MIR17 MIR140 MIR126 INS GCG
7 myeloma, multiple 30.9 MIR21 MIR199A1 MIR17 MIR155 MIR142 MIR140
8 respiratory failure 30.8 SERPINA3 MIR21 MIR199A1 MIR17 MIR155 MIR146A
9 lipid metabolism disorder 30.8 SERPINA3 MIR223 MIR21 MIR199A1 MIR17 MIR144
10 esophageal cancer 30.8 MIR423 MIR29A MIR223 MIR21 MIR199A1 MIR17
11 overnutrition 30.8 SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
12 lipoprotein quantitative trait locus 30.8 SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
13 hepatocellular carcinoma 30.8 SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
14 microvascular complications of diabetes 5 30.8 MIR223 MIR21 MIR199A1 MIR17 MIR126 INS
15 alcohol use disorder 30.7 SERPINA3 MIR29A MIR199A1 INS H2AC18 CCR6
16 allergic disease 30.7 SERPINA3 MIR21 MIR155 ICOSLG H2AC18 CCR6
17 adrenal gland disease 30.6 MIR210 INS CCR6
18 mild cognitive impairment 30.6 SERPINA3 MIR142 INS
19 phosphoglycerate kinase 1 deficiency 11.1
20 hypoglycemia 11.1
21 autoimmune disease of gastrointestinal tract 10.7 SERPINA3 MIR223 MIR21 MIR199A1 MIR142 MIR126
22 muscle tissue disease 10.7 SERPINA3 MIR21 MIR199A1 MIR142 MIR140 MIR126
23 muscular disease 10.7 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR140
24 integumentary system disease 10.7 SERPINA3 MIR423 MIR223 MIR21 MIR199A1 MIR17
25 extrinsic cardiomyopathy 10.7 SERPINA3 MIR423 MIR223 MIR21 MIR199A1 MIR17
26 leukocyte disease 10.7 SERPINA3 MIR21 MIR199A1 MIR17 MIR155 MIR142
27 myopathy 10.7 SERPINA3 MIR423 MIR21 MIR199A1 MIR142 MIR140
28 ovary epithelial cancer 10.7 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR140
29 pancreatic ductal adenocarcinoma 10.7 SERPINA3 MIR223 MIR210 MIR21 MIR199A1 MIR17
30 lysosomal storage disease 10.7 SERPINA3 MIR423 MIR29A MIR21 MIR199A1 MIR17
31 dilated cardiomyopathy 10.7 SERPINA3 MIR423 MIR21 MIR199A1 MIR17 MIR146A
32 bone inflammation disease 10.7 SERPINA3 MIR29A MIR223 MIR210 MIR21 MIR199A1
33 lung disease 10.7 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
34 skin disease 10.7 SERPINA3 MIR423 MIR223 MIR21 MIR199A1 MIR17
35 peripheral nervous system neoplasm 10.7 SERPINA3 MIR29A MIR21 MIR199A1 MIR17 MIR144
36 pulmonary disease, chronic obstructive 10.7 SERPINA3 MIR223 MIR21 MIR199A1 MIR17 MIR144
37 bone disease 10.7 SERPINA3 MIR223 MIR210 MIR21 MIR199A1 MIR17
38 heart conduction disease 10.7 SERPINA3 MIR423 MIR223 MIR21 MIR199A1 MIR17
39 disease of mental health 10.7 SERPINA3 MIR29A MIR223 MIR21 MIR199A1 MIR17
40 demyelinating disease 10.7 SERPINA3 MIR223 MIR21 MIR155 MIR146A MIR142
41 autoimmune disease of skin and connective tissue 10.7 SERPINA3 MIR223 MIR21 MIR17 MIR155 MIR146A
42 heart valve disease 10.7 SERPINA3 MIR423 MIR21 MIR199A1 MIR17 MIR146A
43 interstitial lung disease 10.7 SERPINA3 MIR29A MIR223 MIR21 MIR199A1 MIR155
44 malignant exocrine pancreas neoplasm 10.7 SERPINA3 MIR223 MIR21 MIR199A1 MIR17 MIR144
45 autoimmune disease of musculoskeletal system 10.7 SERPINA3 MIR423 MIR223 MIR210 MIR21 MIR199A1
46 autonomic nervous system neoplasm 10.7 MIR29A MIR21 MIR199A1 MIR17 MIR144 MIR142
47 chromosomal disease 10.7 SERPINA3 MIR223 MIR21 MIR199A1 MIR17 MIR155
48 biliary tract disease 10.7 SERPINA3 MIR29A MIR21 MIR199A1 MIR17 MIR144
49 physical disorder 10.7 SERPINA3 MIR423 MIR21 MIR199A1 MIR17 MIR146A
50 bile duct disease 10.7 SERPINA3 MIR29A MIR21 MIR199A1 MIR17 MIR144

Graphical network of the top 20 diseases related to Glucose Metabolism Disease:



Diseases related to Glucose Metabolism Disease

Symptoms & Phenotypes for Glucose Metabolism Disease

Drugs & Therapeutics for Glucose Metabolism Disease

Drugs for Glucose Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin glargine Approved Phase 4 160337-95-1 118984454
2
Lopinavir Approved Phase 4 192725-17-0 92727
3
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
4
Zidovudine Approved Phase 4 30516-87-1 35370
5
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
6
Pitavastatin Approved Phase 4 147511-69-1 5282452
7
Diazoxide Approved Phase 4 364-98-7 3019
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Iron Approved Phase 4 7439-89-6 29936
10 Anti-Infective Agents Phase 4
11 Black Currant Phase 4
12 Antiviral Agents Phase 4
13 HIV Protease Inhibitors Phase 4
14
protease inhibitors Phase 4
15 Anti-Retroviral Agents Phase 4
16 Lamivudine, zidovudine drug combination Phase 4
17 Anti-HIV Agents Phase 4
18 Cytochrome P-450 Enzyme Inhibitors Phase 4
19 Cytochrome P-450 CYP3A Inhibitors Phase 4
20 Reverse Transcriptase Inhibitors Phase 4
21 Antihypertensive Agents Phase 4
22 Vasodilator Agents Phase 4
23 Hormones Phase 4
24 Calcium, Dietary Phase 4
25 Pharmaceutical Solutions Phase 4
26
Calcium Nutraceutical Phase 4 7440-70-2 271
27
Ramipril Approved Phase 3 87333-19-5 5362129
28
Acarbose Approved, Investigational Phase 3 56180-94-0 441184 444254
29
Glucagon Approved Phase 3 16941-32-5 16133228 16186314
30
Aluminum sulfate Approved Phase 3 10043-01-3
31
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
32
Tirzepatide Approved, Investigational Phase 3 2023788-19-2 156588324
33
Dulaglutide Approved, Investigational Phase 3 923950-08-7
34
Dapagliflozin Approved Phase 3 461432-26-8 9887712
35
Metformin Approved Phase 3 1115-70-4, 657-24-9 4091
36
Linagliptin Approved Phase 3 668270-12-0 57389748 10096344
37
Rosiglitazone Approved, Investigational Phase 3 122320-73-4, 155141-29-0 77999
38
Fenofibrate Approved Phase 3 49562-28-9 3339
39
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
40
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
41
L-Glutamine Approved, Investigational, Nutraceutical Phase 3 56-85-9 5961
42
Gastric inhibitory polypeptide Investigational Phase 3 100040-31-1
43
2,4-thiazolidinedione Investigational Phase 3 2295-31-0 5437
44 Angiotensin-Converting Enzyme Inhibitors Phase 3
45 Trace Elements Phase 3
46 Micronutrients Phase 3
47 Glucagon-Like Peptide 1 Phase 3
48 Adjuvants, Immunologic Phase 3
49 Calciferol Phase 3
50 Immunologic Factors Phase 3

Interventional clinical trials:

(show top 50) (show all 185)
# Name Status NCT ID Phase Drugs
1 Exploring the Association Between Phthalates Exposure, Measured Through Their Urinary Metabolites, and Renal Function Impairment in Individuals With TYpe 2 Diabetes - SGLT2 Subprotocol Unknown status NCT04242758 Phase 4 Dapagliflozin 10 MG;Hydrochlorothiazide 12.5mg
2 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study Completed NCT02689765 Phase 4
3 One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements Completed NCT00483769 Phase 4 Glargine
4 A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism Completed NCT00192621 Phase 4 Combivir (zidovudine [AZT] / lamivudine [3TC]);Kaletra (lopinavir [LPVr])
5 Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed NCT00108615 Phase 4 Metformin;Pioglitazone
6 Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in Acute Myocardial Infarction (AMI) Patients With Abnormal Glucose Metabolism: a Multicenter Prospective Randomized Clinical Trial Recruiting NCT04945122 Phase 4 Pitavastatin;Atorvastatin
7 Comparison of Oral Semaglutide With Matched Oral Semaglutide Placebo as an Early Treatment for Latino Adults With Type 2 Diabetes Receiving Enhanced Lifestyle Care Recruiting NCT04938388 Phase 4 Semaglutide Pill
8 The Impact of Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in Short-term Intensive Insulin Therapy(SIIT) Recruiting NCT05084079 Phase 4 CSII with formula-based initial insulin regimen;CSII with weight-based initial insulin regimen
9 Central Mechanisms That Regulate Glucose Metabolism in Humans Active, not recruiting NCT01028846 Phase 4 Diazoxide;Placebo
10 A 24-week, Multi-center, Randomized, Open-Label Clinical Trial to Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes (XTREME Study) Not yet recruiting NCT05238012 Phase 4 Xuezhikang Capsule;Atorvastatin Calcium Tablets
11 A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age. Terminated NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
12 Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance Withdrawn NCT00306826 Phase 4 pioglitazone;simvastatin;pioglitazone + simvastatin
13 The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial Completed NCT00095654 Phase 3 Ramipril;Rosiglitazone
14 Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study) Completed NCT00221156 Phase 3 Acarbose
15 A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin. Completed NCT00362323 Phase 3 fenofibrate (F) + metformin (M) hydrochloride fixed combination;Metformin
16 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia. Completed NCT00349128 Phase 2, Phase 3 fenofibrate and metformin combination (drug)
17 An Open Label, Parallel-Arm, Multicenter Trial Assessing the Acceptability of 4 Dosages of a New Fixed Dose Combination of Fenofibrate and Metformin in Patients With Type 2 Diabetes and Dyslipidemia Completed NCT00348725 Phase 3 fenofibrate and metformin fixed combination (drug)
18 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both Recruiting NCT05260021 Phase 3 Tirzepatide Dose 1;Tirzepatide Dose 2;Placebo
19 A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype Recruiting NCT05018585 Phase 3
20 A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN) Active, not recruiting NCT04809220 Phase 3 Dulaglutide;Biguanide (BG);Sulfonylurea (SU);Alpha-Glucosidase Inhibitors (α-GI);Thiazolidinedione (TZD);Glinides (GLN);Sodium-glucose cotransporter type 2 inhibitors (SGLT2i)
21 A Multi-center, Randomized, Double-Blind, Active-controlled, Phase 3, Study to Evaluate the Efficacy and Safety of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin Not yet recruiting NCT05505994 Phase 3 DWP16001;Dapagliflozin;DWP16001 Placebo;Dapagliflozin Placebo
22 Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Terminated NCT04371978 Phase 3 Linagliptin 5 MG
23 Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Effect of Omega-3 Fatty Acids on Vascular Function and Inflammation Terminated NCT00935766 Phase 3 Omega-3;Placebo
24 A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Terminated NCT00361868 Phase 3 fenofibrate (F) + metformin (M) hydrochloride fixed combination;Rosiglitazone
25 Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Unknown status NCT03682640 Phase 2 Azithromycin Monohydrate;Insulin Lispro
26 Efficacy and Safety of Transplantation of Autologous Stem Cells Into Pancreatic Artery, Combined With Immunomodulation for the Treatment of Type 1 Diabetes Mellitus Completed NCT02644759 Phase 1, Phase 2
27 Comparaison d'Une Nouvelle Technique de Mesure de l'insulinorésistance Par Scintigraphie Avec la Technique de référence : Utilisation du 6-DIG Comme Marqueur du Transport du Glucose. Completed NCT02102737 Phase 2 6-DIG
28 Phase 1 Study of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes Completed NCT01935804 Phase 2 Pioglitazone;Metformin
29 A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered Into Lymph Nodes Combined With Oral Vitamin D to Investigate the Impact on the Progression of Type 1 Diabetes Completed NCT03345004 Phase 2
30 Acute Metabolic Effects of Melatonin Treatment Completed NCT03204877 Phase 1, Phase 2 Melatonin
31 An Open-label, Three-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of Overnight Closed-loop in Comparison With CGM Alone in the Home Setting in Children and Adolescents With Type 1 Diabetes Completed NCT01778348 Phase 2
32 Effect of Inhibition Soluble Epoxide Hydrolase on Insulin Sensitivity in Humans Completed NCT03486223 Phase 2 GSK2256294;Placebo oral capsule
33 IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes Recruiting NCT04227769 Phase 2 Anakinra Prefilled Syringe
34 Glucose Metabolism in South Asian Women With IGT or IFG. DIAbetes in South Asians - DIASA 3: A 12-week Intervention Trial With Oral Antidiabetic Medication to Improve Hepatic and Whole Body Insulin Sensitivity Recruiting NCT04662866 Phase 2 Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg
35 OsteoPreP: The Effect of Probiotic Supplementation on Bone, Muscle, and Glucose Metabolism in Postmenopausal Women: A Randomised Placebo-controlled Trial Recruiting NCT05348694 Phase 1, Phase 2
36 Regulation of Endogenous Glucose Production by Central KATP Channels Recruiting NCT03540758 Phase 2 Diazoxide;Nicotinic acid;Placebo
37 Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D) Active, not recruiting NCT03181399 Phase 2 Triheptanoin
38 Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide Active, not recruiting NCT03566511 Phase 2 Diazoxide;Placebo
39 An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D) Not yet recruiting NCT05565248 Phase 1, Phase 2
40 A Double-Blind, Placebo-Controlled, Cross-over Trial, Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults Not yet recruiting NCT04824872 Phase 2 Dasiglucagon;Placebo
41 The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients Suspended NCT03685773 Phase 2 Diazoxide;Placebo (for diazoxide);Nicotinic acid
42 Metabolic Effects of Melatonin Treatment Completed NCT03859934 Phase 1 Melatonin;Placebo Oral Tablet
43 Aldosterone and the Metabolic Syndrome: Renin Inhibition Versus Mineralocorticoid Receptor (MR) Antagonism Completed NCT01103245 Phase 1 Hydrochlorothiazide (HCTZ);Aliskiren 150 mg (ALI 150);Spironolactone (SPL 25);Aliskiren 300 mg (ALI 300);Spironolactone 50 mg (SPL 50)
44 A Phase 1 Placebo-Controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Food Effect of Single Escalating Oral Doses of PF-04991532 in Healthy Adult Subjects Completed NCT01102673 Phase 1 PF-04991532;Placebo
45 A Phase 1 Placebo-Controlled Trial to Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses of PF-04991532 in Adult Patients With Type 2 Diabetes Mellitus (T2DM) Completed NCT01129258 Phase 1 PF-04991532;Placebo
46 A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Dose Escalation Study In Japanese Healthy Subjects, And Open Label, Single Dose Study In Western Healthy Subjects To Investigate The Safety, Tolerability, And Pharmacokinetics of PF-04991532. Completed NCT01369277 Phase 1 PF-04991532;Placebo
47 A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 In Otherwise Healthy Overweight And Obese Subjects Completed NCT01757756 Phase 1 Pf-05175157;placebo;midazolam
48 A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus Completed NCT01301456 Phase 1
49 An Open-Label, First-In-Human Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D) Recruiting NCT05210530 Phase 1
50 Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial Active, not recruiting NCT03041363 Phase 1 Triheptanoin

Search NIH Clinical Center for Glucose Metabolism Disease

Cochrane evidence based reviews: glucose metabolism disorders

Genetic Tests for Glucose Metabolism Disease

Anatomical Context for Glucose Metabolism Disease

Organs/tissues related to Glucose Metabolism Disease:

MalaCards : Liver, Spinal Cord, Endothelial, Cortex, Brain, Colon, Heart

Publications for Glucose Metabolism Disease

Articles related to Glucose Metabolism Disease:

(show top 50) (show all 70)
# Title Authors PMID Year
1
Re-interpretation of the mechanism of type 2 diabetes mellitus based on a framework of psychosomatic medicine: a real-world study. 62
36348380 2022
2
Smoking causes the disorder of glucose metabolism under different levels of blood pressure in male occupational population. 62
35942933 2022
3
Metabolites of Gut Microbiota and Possible Implication in Development of Diabetes Mellitus. 62
35549332 2022
4
Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice. 62
35246007 2022
5
Glucose Counteracts Isoprenaline Effects on Ion Channel Functions in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. 62
35323624 2022
6
Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy. 62
35747168 2022
7
Non-Alcoholic Fatty Liver Disease (NAFLD) Is an Independent Risk Factor for Developing New-Onset Diabetes After Acute Pancreatitis: A Multicenter Retrospective Cohort Study in Chinese Population. 62
35692404 2022
8
Observation of Curative Effect of Trimetazidine Combined with Metoprolol in Elderly Patients with Coronary Heart Disease Complicated with Heart Failure and the Effect of Myocardial Remodeling by Integrated Traditional Chinese and Western Medicine. 62
36246960 2022
9
The Degree of Menstrual Disturbance Is Associated With the Severity of Insulin Resistance in PCOS. 62
35769085 2022
10
Effect of glucose metabolism disorders on the short-term prognosis in neonates with asphyxia: a multicenter study in Hubei Province, China. 62
34911602 2021
11
Maternal Metabolites Associated With Gestational Diabetes Mellitus and a Postpartum Disorder of Glucose Metabolism. 62
34255031 2021
12
Associations of urinary carbon disulfide metabolite with oxidative stress, plasma glucose and risk of diabetes among urban adults in China. 62
33250290 2021
13
Diabetes is not (only) a disorder of glucose metabolism! 62
33230859 2021
14
Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1-Foxo1 and PI3K-Akt signalling pathways. 62
32961025 2020
15
Fanconi-Bickel syndrome in a Ugandan child - diagnostic challenges in resource-limited settings: a case report. 62
32993803 2020
16
The metabolic changes in the hippocampus of an atherosclerotic rat model and the regulation of aerobic training. 62
32240489 2020
17
Astaxanthin Encapsulated in Biodegradable Calcium Alginate Microspheres for the Treatment of Hepatocellular Carcinoma In Vitro. 62
31811643 2020
18
The Role of PPARδ Agosnist GW501516 in Rats with Gestational Diabetes Mellitus. 62
32669864 2020
19
Effect of sidt2 Gene on Cell Insulin Resistance and Its Molecular Mechanism. 62
32964053 2020
20
Diabetic Neuropathy. 62
31639839 2019
21
Glucose metabolic alterations in hippocampus of diabetes mellitus rats and the regulation of aerobic exercise. 62
29113873 2019
22
[Compound traditional Chinese medicine in treatment of diabetes]. 62
30989971 2019
23
PREGNANCY OUTCOME IN GESTATIONAL DIABETES COMPARED TO BODY MASS INDEX. 62
31363323 2019
24
Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. 62
30451720 2019
25
Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment. 62
30704150 2019
26
Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. 62
30208453 2018
27
Takotsubo cardiomyopathy: FDG myocardial uptake pattern in fasting patients. Comparison of PET/CT, SPECT, and ECHO results. 62
28054182 2018
28
Susceptible and Prognostic Genetic Factors Associated with Diabetic Peripheral Neuropathy: A Comprehensive Literature Review. 62
29736170 2018
29
Recent Updates on Novel Approaches in Insulin Drug Delivery: A Review of Challenges and Pharmaceutical Implications. 62
29792143 2018
30
Oral Insulin: Myth or Reality. 62
28637407 2018
31
Incorporating Oral Health as Part of Routine Diabetes Care in Ireland. 62
29465850 2017
32
In vitro and in silico interaction of porcine α-amylase with Vicia faba crude seed extract and evaluation of antidiabetic activity. 62
27791455 2017
33
[Piperine regulates glucose metabolism disorder in HepG2 cells of insulin resistance models via targeting upstream target of AMPK signaling pathway]. 62
28952262 2017
34
[Management of hyperglycemic/diabetic patient during and in the immediate follow-up of an acute coronary syndrome]. 62
27374266 2016
35
[Posttransplantation diabetes mellitus in patients after kidney transplantation - Incidence and risk factors]. 62
27642745 2016
36
Oxidative Stress-Activated NHE1 Is Involved in High Glucose-Induced Apoptosis in Renal Tubular Epithelial Cells. 62
27401659 2016
37
[Disorder of glucose metabolism (hypoglycemia, hyperglycemia)]. 62
25831798 2015
38
Costus afer Possesses Carbohydrate Hydrolyzing Enzymes Inhibitory Activity and Antioxidant Capacity In Vitro. 62
26246844 2015
39
Detection of diabetic metabolism disorders post-mortem--forensic case reports on cause of death hyperglycaemia. 62
23620079 2013
40
Modes of inhibition of α -amylase and α -glucosidase by aqueous extract of Morinda lucida Benth leaf. 62
24455701 2013
41
[Research progress of effect of anti-diabetic traditional Chinese medicines based on regulation of glucose metabolic enzyme]. 62
23477131 2012
42
Diabetes: glycaemic control in type 2 (drug treatments). 62
23862772 2012
43
[The insulin regulation of metabolism of fat acids and glucose next in the realization of biologic function of locomotion]. 62
22834149 2012
44
The usefulness of glycated hemoglobin A1c (HbA1c) for identifying dysglycemic states in individuals without previously diagnosed diabetes. 62
22968341 2012
45
Continuous glucose monitoring by means of mid-infrared transmission laser spectroscopy in vitro. 62
21274463 2011
46
Acute hepatocellular and cholestatic injury during therapy with hydrochlorothiazide - clinicohistopathologic findings: a case report. 62
20964809 2010
47
Inflammation and insulin resistance: an old story with new ideas. 62
20617073 2010
48
An association between stress-induced disruption of the hypothalamic-pituitary-adrenal axis and disordered glucose metabolism in an animal model of post-traumatic stress disorder. 62
19732290 2009
49
Normal and abnormal maternal metabolism during pregnancy. 62
18986856 2009
50
Myasthenia gravis in a patient affected by glycogen storage disease type Ib: a further manifestation of an increased risk for autoimmune disorders? 62
18437526 2008

Variations for Glucose Metabolism Disease

Expression for Glucose Metabolism Disease

Search GEO for disease gene expression data for Glucose Metabolism Disease.

Pathways for Glucose Metabolism Disease

GO Terms for Glucose Metabolism Disease

Cellular components related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
2 RISC complex GO:0016442 9.74 MIR126 MIR140 MIR142 MIR144 MIR146A MIR155
3 extracellular vesicle GO:1903561 9.46 MIR29A MIR21 MIR17 MIR126

Biological processes related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.09 INS MIR140 MIR144 MIR146A MIR17 MIR21
2 cellular response to lipopolysaccharide GO:0071222 9.93 MIR223 MIR21 MIR17 MIR146A MIR140
3 positive regulation of protein kinase B signaling GO:0051897 9.93 MIR29A MIR21 MIR199A1 MIR126 INS
4 positive regulation of angiogenesis GO:0045766 9.91 MIR29A MIR210 MIR21 MIR199A1 MIR126
5 cellular response to hypoxia GO:0071456 9.88 MIR17 MIR146A MIR140 MIR126
6 negative regulation of inflammatory response GO:0050728 9.88 MIR223 MIR199A1 MIR146A MIR142 MIR126
7 negative regulation of gene expression GO:0010629 9.85 MIR29A MIR21 MIR199A1 MIR17 MIR155 MIR146A
8 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.77 MIR21 MIR17 MIR146A
9 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.74 MIR223 MIR21 MIR146A
10 positive regulation of vascular endothelial cell proliferation GO:1905564 9.72 MIR29A MIR21 MIR126
11 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.7 MIR140 MIR21 MIR223
12 miRNA-mediated gene silencing GO:0035195 9.68 MIR423 MIR29A MIR223 MIR210 MIR21 MIR199A1
13 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.67 MIR21 MIR146A MIR126
14 miRNA-mediated gene silencing by mRNA destabilization GO:0035279 9.62 MIR223 MIR210 MIR146A MIR140
15 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.59 MIR199A1 MIR17
16 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR21 MIR17
17 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.58 MIR210 MIR21 MIR17
18 negative regulation of matrix metallopeptidase secretion GO:1904465 9.56 MIR199A1 MIR146A
19 negative regulation of vascular endothelial growth factor production GO:1904046 9.56 MIR199A1 MIR17 MIR146A MIR140
20 negative regulation of BMP secretion GO:2001285 9.54 MIR210 MIR17 MIR140
21 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.5 MIR126 MIR144 MIR146A MIR17 MIR21 MIR210

Molecular functions related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.73 MIR29A MIR223 MIR210 MIR21 MIR199A1 MIR17
2 mRNA base-pairing translational repressor activity GO:1903231 9.44 MIR423 MIR29A MIR223 MIR210 MIR21 MIR199A1

Sources for Glucose Metabolism Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....